IDEAS home Printed from https://ideas.repec.org/a/nat/nature/v563y2018i7731d10.1038_s41586-018-0600-6.html
   My bibliography  Save this article

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys

Author

Listed:
  • Erica N. Borducchi

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Jinyan Liu

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Joseph P. Nkolola

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Anthony M. Cadena

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Wen-Han Yu

    (Ragon Institute of MGH, MIT, and Harvard)

  • Stephanie Fischinger

    (Ragon Institute of MGH, MIT, and Harvard)

  • Thomas Broge

    (Ragon Institute of MGH, MIT, and Harvard)

  • Peter Abbink

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Noe B. Mercado

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Abishek Chandrashekar

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • David Jetton

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Lauren Peter

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Katherine McMahan

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Edward T. Moseley

    (Beth Israel Deaconess Medical Center, Harvard Medical School)

  • Elena Bekerman

    (Gilead Sciences)

  • Joseph Hesselgesser

    (Gilead Sciences)

  • Wenjun Li

    (University of Massachusetts Medical School)

  • Mark G. Lewis

    (Bioqual)

  • Galit Alter

    (Ragon Institute of MGH, MIT, and Harvard)

  • Romas Geleziunas

    (Gilead Sciences)

  • Dan H. Barouch

    (Beth Israel Deaconess Medical Center, Harvard Medical School
    Ragon Institute of MGH, MIT, and Harvard)

Abstract

The latent viral reservoir is the critical barrier for the development of a cure for HIV-1 infection. Previous studies have shown direct antiviral activity of potent HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) administered when antiretroviral therapy (ART) was discontinued, but it remains unclear whether bNAbs can target the viral reservoir during ART. Here we show that administration of the V3 glycan-dependent bNAb PGT121 together with the Toll-like receptor 7 (TLR7) agonist vesatolimod (GS-9620) during ART delayed viral rebound following discontinuation of ART in simian–human immunodeficiency virus (SHIV)-SF162P3-infected rhesus monkeys in which ART was initiated during early acute infection. Moreover, in the subset of monkeys that were treated with both PGT121 and GS-9620 and that did not show viral rebound after discontinuation of ART, adoptive transfer studies and CD8-depletion studies also did not reveal virus. These data demonstrate the potential of bNAb administration together with innate immune stimulation as a possible strategy for targeting the viral reservoir.

Suggested Citation

  • Erica N. Borducchi & Jinyan Liu & Joseph P. Nkolola & Anthony M. Cadena & Wen-Han Yu & Stephanie Fischinger & Thomas Broge & Peter Abbink & Noe B. Mercado & Abishek Chandrashekar & David Jetton & Laur, 2018. "Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys," Nature, Nature, vol. 563(7731), pages 360-364, November.
  • Handle: RePEc:nat:nature:v:563:y:2018:i:7731:d:10.1038_s41586-018-0600-6
    DOI: 10.1038/s41586-018-0600-6
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41586-018-0600-6
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1038/s41586-018-0600-6?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Xiaolei Wang & Eunice Vincent & Summer Siddiqui & Katherine Turnbull & Hong Lu & Robert Blair & Xueling Wu & Meagan Watkins & Widade Ziani & Jiasheng Shao & Lara A. Doyle-Meyers & Kasi E. Russell-Lodr, 2022. "Early treatment regimens achieve sustained virologic remission in infant macaques infected with SIV at birth," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    2. Miriam Rosás-Umbert & Jesper D. Gunst & Marie H. Pahus & Rikke Olesen & Mariane Schleimann & Paul W. Denton & Victor Ramos & Adam Ward & Natalie N. Kinloch & Dennis C. Copertino & Tuixent Escribà & An, 2022. "Administration of broadly neutralizing anti-HIV-1 antibodies at ART initiation maintains long-term CD8+ T cell immunity," Nature Communications, Nature, vol. 13(1), pages 1-12, December.
    3. Victoria E. K. Walker-Sperling & Noe B. Mercado & Abishek Chandrashekar & Erica N. Borducchi & Jinyan Liu & Joseph P. Nkolola & Mark Lewis & Jeffrey P. Murry & Yunling Yang & Romas Geleziunas & Merlin, 2022. "Therapeutic efficacy of combined active and passive immunization in ART-suppressed, SHIV-infected rhesus macaques," Nature Communications, Nature, vol. 13(1), pages 1-8, December.

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:563:y:2018:i:7731:d:10.1038_s41586-018-0600-6. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.